Rigel Pharmaceuticals | RIGL - Sales Revenues


Rigel Pharmaceuticals reported $55.31M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agenus USD 33.7M 500K Mar/2026
Amgen USD 10.1B 1.48B Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Celldex Therapeutics USD 22K 7K Jun/2026
Daiichi Sankyo JPY 574.74B 12.26B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Veracyte USD 150.32M 11.25M Jun/2026